⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30376677 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL29698865 | 0.98 | NOS2 (0.48) | — | |
| Formic Acid SCHEMBL27813486 | 0.88 | PARP1 (0.41) | — | |
| SCHEMBL13623090 | 0.87 | ASIC3 (0.48) | — | |
| SCHEMBL1540707 | 0.82 | NOS2 (0.52) | — | |
| SCHEMBL29698872 | 0.82 | NOS2 (0.52) | — | |
| SCHEMBL45869 | 0.82 | KCNH2 (0.52) | — | |
| SCHEMBL11564452 | 0.79 | KCNH2 (0.50) | — | |
| SCHEMBL1269597 | 0.79 | KCNH2 (0.62) | — | |
| SCHEMBL317714 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 520 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2802590-A1 | THIENOPYRIMIDINE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2014-11-19 | — | — | EP | claimed |
| WO-2013104575-A1 | THIENOPYRIMIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-18 | — | — | WO | claimed |
| US-20130178460-A1 | THIENOPYRIMIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | claimed |
| EP-1844044-B1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-07-21 | — | — | EP | claimed |
| US-7678815-B2 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | claimed |
| US-7482341-B2 | N-(pyridin-2-yl)-benzenesulfonamides; antidiabetic agents for Type II Diabetes; obesity; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-01-27 | — | — | US | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| JP-2008515826-A | — | — | 2008-05-15 | — | — | JP | claimed |
| EP-1844044-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | claimed |
| WO-2006037501-A9 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | HOFFMANN LA ROCHE (CH) | 2007-08-02 | — | — | WO | claimed |
| US-6949562-B2 | Heterocyclic compounds as ligands of the GABAA receptor | NEUROGEN CORPORATION (US) | 2005-09-27 | — | — | US | claimed |
| CN-1164568-C | Process for condensating salicyladehyde with arylamine | 中国科学院化学研究所 | 2004-09-01 | — | — | CN | claimed |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | YOHANNES DANIEL (US) | 2004-06-10 | — | — | US | claimed |
| CN-1139606-C | Norbornene catalytic system and its preparation method and application | 中国科学院化学研究所 | 2004-02-25 | — | — | CN | claimed |
| US-6673811-B1 | TREATMENT OF ANXIETY, DEPRESSION, SLEEP DISORDER, ATTENTION DEFICIT DISORDER, ALZHEIMER'S DEMENTIA, OR SHORT-TERM MEMORY LOSS | NEUROGEN CORPORATION | 2004-01-06 | — | — | US | claimed |
| EP-1325006-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABA A? RECEPTOR | NEUROGEN CORPORATION (US) | 2003-07-09 | — | — | EP | claimed |
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | PFIZER INC | 2003-06-05 | — | — | US | claimed |
| CN-1394685-A | Norbornene catalytic system and its preparation method and application | CHINESE ACAD INST CHEMISTRY (CN) | 2003-02-05 | — | — | CN | claimed |
| CN-1386735-A | Process for condensating salicyladehyde with arylamine | CHINESE ACAD INST CHEMISTRY (CN) | 2002-12-25 | — | — | CN | claimed |
| WO-2002012442-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABAA RECEPTOR | NEUROGEN CORPORATION (US) | 2002-02-14 | — | — | WO | claimed |